Clinical spectrum of SCN2A mutations

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• SCN2A gene mutations are implicated in diverse epilepsy syndromes such as benign familial neonatal-infantile seizures (BFNIS), genetic epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS).
• Over ten missense mutations in SCN2A have been identified in BFNIS cases, while a single nonsense mutation was found in a patient with severe epilepsy and cognitive impairment.

Purpose of the Study:

• To investigate the impact of SCN2A mutations on neuronal sodium channel function and expression.
• To explore the relationship between SCN2A genotype and epilepsy phenotype.

Main Methods:

• Analysis of SCN2A gene mutations in epilepsy patients.
• Functional studies of SCN2A mutations to assess biophysical defects and cell surface expression of Na(V)1.2 channels.

Main Results:

• SCN2A mutations can lead to varied biophysical defects in the neuronal sodium channel Na(V)1.2.
• Impaired cell surface expression of Na(V)1.2 was observed due to SCN2A mutations.
• A microduplication on chromosome 2q24.3, encompassing SCN2A, was linked to inherited neonatal seizures and intellectual disability.

Conclusions:

• SCN2A mutations are a significant cause of various epilepsy syndromes.
• Functional consequences of SCN2A mutations include altered channel biophysics and expression.
• The relationship between SCN2A genotype and epilepsy phenotype is not consistently defined.